The progression to castration-resistant prostate cancer (CRPC) correlates with gain-of-
function of the androgen receptor (AR) and activation of AKT. However, as single agents, AR …

Abstract Treatment options for metastatic castration-resistant prostate cancer (CRPC) have
evolved with the established benefit of the novel androgen receptor (AR)-targeted agents …

Background Castration-resistant prostate cancer (CRPC) occurs when prostate cancer
(CaP) progresses under therapy-induced castrate conditions. Several mechanisms have …

Continued androgen receptor (AR) signaling is an established mechanism underlying
castration-resistant prostate cancer (CRPC), and suppression of androgen receptor …

Androgen receptor (AR), a ligand-dependent nuclear transcription factor and a member of
steroid hormone receptor family, plays an important role in prostate organogenesis by …

Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has
improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC) …

Purpose: Persistent androgen receptor (AR) signaling drives castration-resistant prostate
cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic …

Castration-resistant prostate cancer, or CRPC, is an aggressive stage of prostate cancer
(PCa) in which PCa cells invade nearby or other parts of the body. When a patient with PCa …

Gonadal androgen suppression (castration via orchiectomy or gonadotropin-releasing
hormone analogues) suppresses circulating testosterone levels but does not achieve …

Castration-resistant prostate cancer (CRPC) is defined by resistance of the tumor to
androgen deprivation therapy (ADT). Several molecular changes, particularly in the AR …